medicina57巻1号

2020年01月発行

特集 今の流れに乗り遅れない！—プライマリ・ケアでの呼吸器疾患の診かた・薬の使いかた 最新の肺炎診療の考えかた

肺炎球菌ワクチンとインフルエンザワクチンの最近の考えかた

著者： 山藤栄一郎¹

所属機関： ¹長崎大学熱帯医学研究所臨床感染症学分野

ページ範囲：P.72 - P.77

Point
◎日本で小児への肺炎球菌ワクチンを定期接種化後，成人でも血清型置換現象が認められた．
◎肺炎球菌ワクチンもインフルエンザワクチンも，対象者に接種を推奨する．
◎ワクチンの効果は，個人レベルでの効果と，集団レベルでの効果，それぞれを鑑みる必要がある．

参考文献

1）MMWR：Antiviral agents for the treatment and chemoprophylaxis of influenza；Recommendations of the Advisory Committee on Immunization Practices （ACIP）. Centers for Disease Control and Prevention, 2011

2）Watanabe A, et al：Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza；A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51：1167-1175, 2010

3）Katsumi Y, et al：Effect of a single inhalation of laninamivir octanoate in children with influenza. Pediatrics 129：e1431-1436, 2012

4）Sugaya N, Ohashi Y：Long-acting neuraminidase inhibitor laninamivir octanoate （CS-8958） versus oseltamivir as treatment for children with influenza virus infection. Antimicrob agents chemother 54：2575-2582, 2010

5）Zumla A, et al：Emerging novel and antimicrobial-resistant respiratory tract infections；New drug development and therapeutic options. Lancet Infect Dis 14：1136-1149, 2014

6）Hayden FG, et al：Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J med 379：913-923, 2018

1）Kraicer-Melamed H, et al：The effectiveness of pneumococcal polysaccharide vaccine 23 （PPV23） in the general population of 50 years of age and older；A systematic review and meta-analysis. Vaccine 34：1540-1550, 2016

2）Suzuki M, et al：Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older；A multicentre, prospective, test-negative design study. Lancet Infect Dis 17：313-321, 2017

3）Lucero MG, et al：Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009：CD004977, 2009

4）菅 秀，他：13価肺炎球菌結合型ワクチン（PCV13）導入後の小児侵襲性肺炎球菌感染症（IPD）の現状．IASR 39：1112-1113，2018

5）Sando E, et al：Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults；The Japan Pneumococcal Vaccine Effectiveness Study （J-PAVE）. Vaccine 37：2687-2693, 2019

6）Bonten MJ, et al：Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372：1114-1125, 2015

7）Advisory Committee on Immunization Practices（ACIP） June 2019 Meeting Recommendations. 2019.　https://www.cdc.gov/vaccines/acip/recommendations.html（2019年10月閲覧）

8）Nakashima K, et al：Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals；A randomized, open-label, non-inferiority trial. Hum Vaccin immunother 14：1923-1930, 2018

9）Belongia EA, et al：Variable influenza vaccine effectiveness by subtype；A systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 16：942-951, 2016

10）Saito N, et al：Dose-dependent negative effects of prior multiple vaccinations against influenza A and influenza B among schoolchildren；A Study of Kamigoto Island in Japan During the 2011-2012, 2012-2013, and 2013-2014 Influenza Seasons. Clin Infect Dis 67：897-904, 2018

11）Suzuki M, et al：Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ＞/＝65years in Japan. Vaccine 36：2960-2967, 2018